Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.
Yamamoto, N.; Matsuyama, S.; Hoshino, T.; Yamamoto, N.
Show abstract
In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, Hubei Province, China. No specific treatment has been established against coronavirus disease-2019 (COVID-19) so far. Therefore, it is urgently needed to identify effective antiviral agents for the treatment of this disease, and several approved drugs such as lopinavir have been evaluated. Here, we report that nelfinavir, an HIV-1 protease inhibitor, potently inhibits replication of SARS-CoV-2. The effective concentrations for 50% and 90% inhibition (EC50 and EC90) of nelfinavir were 1.13 {micro}M and 1.76 {micro}M respectively, the lowest of the nine HIV-1 protease inhibitors including lopinavir. The trough and peak serum concentrations of nelfinavir were three to six times higher than EC50 of this drug. These results suggest that nelfinavir is a potential candidate drug for the treatment of COVID-19 and should be assessed in patients with COVID-19.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 96%
- Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice 96%
- Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron variants 96%
Similar papers in this journal
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs 97%
- Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro 96%
- Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production 96%
Similar papers in this journal
- Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell 97%
- In Vitro Activity of Itraconazole Against SARS-CoV-2 95%
- Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures 94%
Similar papers in this journal
- Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors 95%
- In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication 95%
- Antiviral activity of lambda-carrageenan against influenza viruses in mice and severe acute respiratory syndrome coronavirus 2 in vitro 95%
Similar papers in this journal
- Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro 97%
- Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro 95%
- Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.